Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

582 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Maternal liver-related symptoms during pregnancy in primary sclerosing cholangitis.
Nayagam JS, Weismüller TJ, Milkiewicz P, Wronka KM, Bik E, Schramm C, Fuessel K, Zhou T, Chang J, Färkkilä M, Carlsson Y, Lundman A, Cazzagon N, Corrà G, Rigopoulou E, Dalekos GN, Båve AL, Bergquist A, Ben Belkacem K, Marzioni M, Mancinelli M, Verhelst X, Marschall HU, Heneghan MA, Joshi D; International PSC Study Group (IPSCSG). Nayagam JS, et al. Among authors: farkkila m. JHEP Rep. 2023 Oct 31;6(1):100951. doi: 10.1016/j.jhepr.2023.100951. eCollection 2024 Jan. JHEP Rep. 2023. PMID: 38089547 Free PMC article.
Evaluation of Tofacitinib in Primary Sclerosing Cholangitis and Associated Colitis: A Multicenter, Retrospective Study.
Schregel I, Ramos GP, Ioannou S, Culver E, Färkkilä M, Schramm C; International PSC Study Group. Schregel I, et al. Among authors: farkkila m. Clin Gastroenterol Hepatol. 2023 Dec;21(13):3448-3450.e3. doi: 10.1016/j.cgh.2023.01.014. Epub 2023 Jan 31. Clin Gastroenterol Hepatol. 2023. PMID: 36731589 Free article. No abstract available.
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis.
Trauner M, Chung C, Sterling K, Liu X, Lu X, Xu J, Tempany-Afdhal C, Goodman ZD, Färkkilä M, Tanaka A, Trivedi P, Kowdley KV, Bowlus CL, Levy C, Myers RP. Trauner M, et al. Among authors: farkkila m. BMC Gastroenterol. 2023 Mar 15;23(1):75. doi: 10.1186/s12876-023-02653-2. BMC Gastroenterol. 2023. PMID: 36922785 Free PMC article. Clinical Trial.
Magnitude and Time-Trends of Post-Endoscopy Esophageal Adenocarcinoma and Post-Endoscopy Esophageal Neoplasia in a Population-Based Cohort Study: The Nordic Barrett's Esophagus Study.
Wani S, Holmberg D, Santoni G, Kauppila JH, Farkkila M, von Euler-Chelpin M, Shaheen NJ, Lagergren J. Wani S, et al. Among authors: farkkila m. Gastroenterology. 2023 Oct;165(4):909-919.e13. doi: 10.1053/j.gastro.2023.05.044. Epub 2023 Jun 4. Gastroenterology. 2023. PMID: 37279832
HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells.
Zecher BF, Ellinghaus D, Schloer S, Niehrs A, Padoan B, Baumdick ME, Yuki Y, Martin MP, Glow D, Schröder-Schwarz J, Niersch J, Brias S, Müller LM, Habermann R, Kretschmer P, Früh T, Dänekas J, Wehmeyer MH, Poch T, Sebode M; International PSC Study Group (IPSCSG); Ellinghaus E, Degenhardt F, Körner C, Hoelzemer A, Fehse B, Oldhafer KJ, Schumacher U, Sauter G, Carrington M, Franke A, Bunders MJ, Schramm C, Altfeld M. Zecher BF, et al. Gut. 2024 Jan 5;73(2):325-337. doi: 10.1136/gutjnl-2023-329524. Gut. 2024. PMID: 37788895 Free PMC article.
582 results